In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...
1h
Lebanon Daily News on MSNLebanon County to receive another round of opioid settlement funds. How it will be used.Lebanon County is expected to receive $3.6 million from a second wave of opioid settlement funds, which officials will use create new programs.
J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense ...
Alvotech and Teva Pharmaceuticals (“Teva”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review ...
Bank Leumi (TASE: LUMI) led the market today, falling 1.02% on the day's biggest trading turnover. Bank Hapoalim (TASE: POLI) fell 1.37%, Mizrahi Tefahot Bank fell 0.53% and Israel Discount Bank (TASE ...
Johnson & Johnson (NYSE:JNJ) is reportedly suing Samsung Bioepis for breach of contract related to the launch of a biosimilar ...
More than a third (33%) of essential generic medicines were withdrawn from the Portuguese market in the last ten years, ...
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results